[News] Europe is falling behind on targets to address AMR

15th Jan, 2026

Oncology

The Lancet

Antimicrobial resistance (AMR) is causing more than 35 000 deaths per year across Europe. According to estimates by the European Centre for Disease Prevention and Control (ECDC), based on 2024 data submitted by all countries in the EU and European Economic Area, Europe has met only one of five targets set to tackle the issue.

Published By: The Lancet

Oncology

31st Dec, 2025

Journal of the American Medical Association

A Scalable Model to Improve Cancer Care for Older Adults

Oncology

15th Jan, 2026

The Lancet

[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula

Oncology

15th Jan, 2026

The Lancet

[Review] Development of a core outcome set for adolescents and young adults with cancer

Oncology

15th Jan, 2026

The Lancet

[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative

Oncology

15th Jan, 2026

The Lancet

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment

Oncology

15th Jan, 2026

The Lancet

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making

Oncology

15th Jan, 2026

The Lancet

[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial

[News] Europe is falling behind on targets to address AMR

Related Articles

A Scalable Model to Improve Cancer Care for Older Adults

[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula

[Review] Development of a core outcome set for adolescents and young adults with cancer

[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making

[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial

[News] Europe is falling behind on targets to address AMR

Related Articles

A Scalable Model to Improve Cancer Care for Older Adults

[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula

[Review] Development of a core outcome set for adolescents and young adults with cancer

[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment

[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making

[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial